MedTrace Logo

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

NCT03751488 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-08-13

No results posted yet for this study

Summary

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

Conditions

  • Schizo Affective Disorder
  • Schizophrenia
  • Schizoaffective Disorder

Interventions

DRUG

LY03010

Single Dose of LY03010 at 351 mg or 156 mg or 117mg

DRUG

Invega Sustenna 156 MG in 1 ML Prefilled Syringe

Single Dose at 156mg

Sponsors & Collaborators

  • Luye Pharma Group Ltd.

    lead INDUSTRY

Principal Investigators

  • Amy Sun, MD PhD · Luye Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-12
Primary Completion
2019-07-24
Completion
2019-07-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03751488 on ClinicalTrials.gov